Ehave Provides Progress Update on its HPPD Study with University of Melbourne MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the "Company"), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, is pleased to...

Ehave Files 6-K Disclosing Research Project Agreement MIAMI, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced...

Ehave Partners with Globally Recognized University to Target Hallucinogen Persisting Perception Disorder (HPPD) MIAMI, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, today announced a...

Hallucinogen Persisting Perception Disorder (HPPD) Research Initiated By Ehave HPPD is a psychiatric disorder characterized by the persisting presence of sensory disturbances, most commonly visual, that resemble those produced by the use of hallucinogenic substances. Ehave...